BBIO
Price
$38.57
Change
+$0.17 (+0.44%)
Updated
May 2 closing price
Capitalization
7.32B
88 days until earnings call
PMN
Price
$0.64
Change
-$0.01 (-1.54%)
Updated
May 2 closing price
Capitalization
20.92M
16 days until earnings call
Ad is loading...

BBIO vs PMN

Header iconBBIO vs PMN Comparison
Open Charts BBIO vs PMNBanner chart's image
BridgeBio Pharma
Price$38.57
Change+$0.17 (+0.44%)
Volume$3.17M
Capitalization7.32B
ProMIS Neurosciences
Price$0.64
Change-$0.01 (-1.54%)
Volume$18.1K
Capitalization20.92M
BBIO vs PMN Comparison Chart
Loading...
BBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BBIO vs. PMN commentary
May 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBIO is a StrongBuy and PMN is a Hold.

Ad is loading...
COMPARISON
Comparison
May 04, 2025
Stock price -- (BBIO: $38.57 vs. PMN: $0.64)
Brand notoriety: BBIO and PMN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BBIO: 100% vs. PMN: 55%
Market capitalization -- BBIO: $7.32B vs. PMN: $20.92M
BBIO [@Biotechnology] is valued at $7.32B. PMN’s [@Biotechnology] market capitalization is $20.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $306.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BBIO’s FA Score shows that 1 FA rating(s) are green whilePMN’s FA Score has 0 green FA rating(s).

  • BBIO’s FA Score: 1 green, 4 red.
  • PMN’s FA Score: 0 green, 5 red.
According to our system of comparison, BBIO is a better buy in the long-term than PMN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BBIO’s TA Score shows that 5 TA indicator(s) are bullish while PMN’s TA Score has 3 bullish TA indicator(s).

  • BBIO’s TA Score: 5 bullish, 4 bearish.
  • PMN’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, BBIO is a better buy in the short-term than PMN.

Price Growth

BBIO (@Biotechnology) experienced а +6.24% price change this week, while PMN (@Biotechnology) price change was +8.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.30%. For the same industry, the average monthly price growth was +8.07%, and the average quarterly price growth was -4.75%.

Reported Earning Dates

BBIO is expected to report earnings on Jul 31, 2025.

PMN is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+4.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BBIO($7.32B) has a higher market cap than PMN($20.9M). BBIO YTD gains are higher at: 40.561 vs. PMN (-32.475). PMN has higher annual earnings (EBITDA): -391.76K vs. BBIO (-436.83M). BBIO has more cash in the bank: 681M vs. PMN (21.6M). PMN has less debt than BBIO: PMN (4.05M) vs BBIO (1.73B). BBIO has higher revenues than PMN: BBIO (222M) vs PMN (0).
BBIOPMNBBIO / PMN
Capitalization7.32B20.9M35,043%
EBITDA-436.83M-391.76K111,505%
Gain YTD40.561-32.475-125%
P/E RatioN/A5.82-
Revenue222M0-
Total Cash681M21.6M3,153%
Total Debt1.73B4.05M42,741%
FUNDAMENTALS RATINGS
BBIO vs PMN: Fundamental Ratings
BBIO
PMN
OUTLOOK RATING
1..100
437
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
95
Overvalued
PROFIT vs RISK RATING
1..100
78100
SMR RATING
1..100
9791
PRICE GROWTH RATING
1..100
3891
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
n/a21

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BBIO's Valuation (4) in the null industry is significantly better than the same rating for PMN (95). This means that BBIO’s stock grew significantly faster than PMN’s over the last 12 months.

BBIO's Profit vs Risk Rating (78) in the null industry is in the same range as PMN (100). This means that BBIO’s stock grew similarly to PMN’s over the last 12 months.

PMN's SMR Rating (91) in the null industry is in the same range as BBIO (97). This means that PMN’s stock grew similarly to BBIO’s over the last 12 months.

BBIO's Price Growth Rating (38) in the null industry is somewhat better than the same rating for PMN (91). This means that BBIO’s stock grew somewhat faster than PMN’s over the last 12 months.

PMN's P/E Growth Rating (99) in the null industry is in the same range as BBIO (100). This means that PMN’s stock grew similarly to BBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BBIOPMN
RSI
ODDS (%)
Bearish Trend 3 days ago
76%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
87%
MACD
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 4 days ago
82%
Declines
ODDS (%)
Bearish Trend 19 days ago
84%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
67%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
88%
View a ticker or compare two or three
Ad is loading...
BBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPD35.600.68
+1.96%
Simplify US Equity PLUS Dwnsd Cnvxty ETF
RSPH28.710.50
+1.77%
Invesco S&P 500® Equal Wt Hlth Care ETF
SIXO31.830.31
+0.98%
AllianzIM US Lrg Cp 6M Bfr10 Apr/Oct ETF
ECLN31.030.26
+0.85%
First Trust EIP Carbon Impact ETF
CEF28.42-0.04
-0.14%
Sprott Physical Gold and Silver Trust

BBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, BBIO has been loosely correlated with ARGX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BBIO jumps, then ARGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BBIO
1D Price
Change %
BBIO100%
+0.44%
ARGX - BBIO
46%
Loosely correlated
+1.53%
AXON - BBIO
44%
Loosely correlated
+1.14%
ARRY - BBIO
43%
Loosely correlated
-2.52%
PMN - BBIO
43%
Loosely correlated
-1.54%
ROIV - BBIO
41%
Loosely correlated
-0.86%
More

PMN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PMN has been loosely correlated with SYRE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PMN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PMN
1D Price
Change %
PMN100%
-1.54%
SYRE - PMN
44%
Loosely correlated
+3.07%
BBIO - PMN
42%
Loosely correlated
+0.44%
ABOS - PMN
33%
Poorly correlated
+0.93%
LIXT - PMN
27%
Poorly correlated
-0.79%
ARGX - PMN
25%
Poorly correlated
+1.53%
More